Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Name one better . You can’t.
Ahhhh DonDon, is that what his 2/05/1998 arrest was all about? DUI?
The proof is they showed 24% efficacy in S2C.
Maverick you are right ..one may call it anecdotes , or not ,
But as Dr Patterson said , in some patients there is no question that Leronlimab was responsible for patient surviving ..As he said..
" Anecdotes don't come off life support "
[Nader is ] a 2x convicted felon.
these small NIH studies move very slowly. Will they get faster, probably, but Lenz was selected late July 2020!
Some issues with Kiniksa's Mavrilimumab study
Has anyone invested in KNSA since the trial came out showing that GM-CSF is the key to Covid? It seems likely that the government will put money toward an additional trial that includes several different drugs that are anti-GM-CSF. Lenz is obviously the top of the list. But Kiniksa's drug mavrilimumab also has a lot of potential. And their stock is down the last couple of sessions despite announcing FDA approval for recurrent pericarditis last Thursday night. I guess the news was already baked in but it should have popped a bit. No one on the KNSA stocktwits page is even talking about Covid treatment.
https://www.clinicaltrialsarena.com/comment/humanigens-and-kiniksas-anti-gm-csf-antibodies-likely-to-garner-a-place-for-nonventilated-covid-19-patients/
It was recently discovered that the protein GM-CSF is the cytokine responsible for severe Covid and death. Kiniksa will surely get a government grant to do an additional trial. Here is a BBC article about the trial that determined that GM-CSF is key to Covid:
https://www.bbc.com/news/health-56352128
Here is an additional article stating that KNSA and HGEN are the two companies with the best GM-CSF drugs to combat Covid:
https://www.clinicaltrialsarena.com/comment/humanigens-and-kiniksas-anti-gm-csf-antibodies-likely-to-garner-a-place-for-nonventilated-covid-19-patients/
Since lenzilumab will affect all variants equally, this is very good news for HGEN (and very bad news for humanity).
Ex-FDA head warns COVID-19 variant could infect vaccinated New Yorkers
https://nypost.com/2021/03/21/new-yorks-covid-variant-may-infect-vaccinated-residents/
Why they sell, then rebuying? What is the benefit of it?
My guess is that it is a 75% chance that Nomis sold all of their stock. They have clearly wanted to sell all they could and Friday's mammoth sell matches about how many shares they owned. And this is good news. Nomis selling all of their stock precludes them selling any more. The Nomis sales have been a thorn in the side of HGEN since summer. While their sales were never big enough to tank the stock, their sales were definitely enough to prevent the stock from rising to the level it deserved.
If Nomis are done selling, the rise in stock price can now commence in anticipation of trial results. I think that rise started a month ago when HGEN rose to $24. But then Nomis sold a bit and Nasdaq got walloped for a couple of weeks. And then the fiasco where one of lenz's trials was falsely said to have been stopped on a government website. A lot of bad luck over the last month. Rebounds from bad luck almost always happen. No legitimately bad news has come out during this last month's downward spiral in stock price.
It is even possible that Nomis could start rebuying now. Nomis and/or associates might have been the one(s) that bought in the self-created dip on Friday. Tax advantages to selling 28 cent shares could be the motivating reason to sell and then rebuy. They could buy a ton of shares each day this week if they are rebuying. If Monday is green with a lot of volume, it will make me confident for the rest of the week.
There is a drug trial that recently produced great results: aspirin! And notice how they didn't need to look at a 62 patient slice to show positive results.
https://www.cbsnews.com/news/low-dose-aspirin-reduce-risk-severe-illness-death-covid-19/
Researchers studied over 400 patients admitted from March to July 2020 to hospitals all over the country, including GW Hospital, the University of Maryland Medical Center, Wake Forest Baptist Medical Center and Northeast Georgia Health System.
They found aspirin use led to a 44% reduction in the use of ventilators, a 43% reduction in ICU admission and a 47% reduction in in-hospital mortality.
Right, yeah OK, huh huh...quack doctors trying to make a few bucks by treating:
an ongoing low level of inflammation in the brain
an autoimmune condition in which the body makes antibodies that attack the brain
decreased blood flow to the brain, due to abnormalities of the autonomic nervous system
difficulty making enough energy molecules to satisfy the needs of the brain and body.
Inflammation of the lungs
Imagine that?
Leronlimab will save these long haulers as well, in phase 2 and kicking arse
This letter writing campaign is hilarious. All the FDA cares about is the results of trials. The trial failed. End of story. Writing Santa Claus would be just as effective.
I haven't followed the long hauler trial. Is it the same as Chronic Fatigue, Chronic Lyme, and Fibromyalgia where they can't test for it and the doctor has to base the the diagnosis on the symptoms that the patient tells the doctor? I'm not saying that these diseases don't exist but they clearly attract malingerers and hypochondriacs. These kinds of diseases also attract quack doctors looking to make a quick buck.
Have anything that shows Dr.Paterson is delusional?
best-in-class lifesaving drug
The phrase goes "Denial isn't JUST a river in Egypt." Can shorts get anything right?
Dr. Paterson explains it in 1 tweet- To those that call Leronlimab a failure are dead wrong- I guess you know more than he does about medicine? I challenge anyone to show me proof of failure. You can't produce a stitch of facts or any documentation of it so lets move on and watch Cytodyn do its thing and save some lives.
Did not specifically discuss HGEN or other drugs still in trials.
I always thought that CytoDyn's hiring of Chris Recknor stunk to high heaven. Appeared it could be quid pro quo. I would like to see if the patients enrolled in the treatment arm by Recknor did better or worse than patients in the rest of the trial. It isn't difficult to cheat a trial if the company and the trial site are in cahoots.
Since than he has tweeted again stating he’s now 50/50 on approval.
Patient given Aviptadil gives birth
COVID-19 put a 21-year-old on a ventilator. Then she gave birth.
https://www.tampabay.com/news/health/2021/03/15/covid-19-put-a-21-year-old-on-a-respirator-then-she-gave-birth/
Doctors, still looking to be proactive, started her on Aviptadil, a decades-old synthetic form of a natural peptide studied for use in erectile dysfunction and pulmonary fibrosis. It was being trialed as a therapy for COVID-19-related respiratory failure after showing promise in Israel. Khammanivong may have been among the first 100 COVID-19 patients in the U.S. to get it.
Last summer, there was a lot of talk among investors that companies with Covid therapeutic drugs could be bought out. But it wasn't realistic because there were hundreds of different drugs being trialed at the time and no one knew which ones were going to work. No one was going to throw around billions of dollars willy nilly for shot-in-the-dark drugs. But it is now known that GM-CSF is the key to Covid treatment. It is totally realistic that Bill Gates or Big Pharma could try to buy as many anti-GM-CSF drugs as possible. Bill Gates and/or the government putting money towards lenzilumab's production is also a possibility. Gates will likely also put a bunch of money towards building equipment that can detect GM-CSF.
Reasons HGEN is HGREEN today:
1. Stimulus money (should keep coming in all week)
2. Nomis likely stopped selling (Hurray!)
3. GM-CSF is the key to treating Covid (more and more will find out each day)
CytoDyn tries to squeeze positive news out of a failed Covid-19 study
https://www.thepharmaletter.com/article/look-back-at-pharma-news-in-the-week-to-march-12-2021
CytoDyn really, really wanted to put its best foot forward, said Amber Tong on Endpoints News. So much so that, after sitting on unblinded Phase IIb/III data on Vyrologix (leronlimab) in Covid-19 for two weeks pending regulatory discussions, the biotech issued six press releases over the weekend, each offering a little more information or refining what was previously disclosed.
In one of them, CytoDyn acknowledged that leronlimab - an anti-CCR5 antibody that had already been turned away at the FDA’s doorsteps once - had failed the primary endpoint of lowering all-cause mortality at Day 28, as the result was not statistically significant. At best, execs implied, they would need to collect further clinical data to be ready for regulatory reviews.
Further massaging the data, execs pointed out that there were more over-65 patients taking leronlimab than placebo — leading them to conduct a post hoc “age adjustment” analysis and deduce “statistically-significant results (p-value = 0.0319)” for the primary endpoint “in participants receiving leronlimab + ‘commonly used COVID-19 treatments’ compared to participants who received ‘commonly used COVID-19 treatments’ alone in the placebo group in the overall modified intent-to-treat (‘mITT’) population.”
CytoDyn claimed it’s gotten regulators on board with the subgroup hypothesis: The UK’s MHRA is apparently willing to accept data from the open-label extension of the study, which has enrolled 45 so far. The US agency is asking for data from 140 more patients in the critically ill population, with the new primary endpoint of length of hospital stay (according to CytoDyn, leronlimab had shortened time to recovery by six days among these patients compared to placebo plus standard of care only, with a p-value of 0.005). In Canada, the company will apply to start selling the drug while clinical trials continue — with unclear prospects.
Circumstantial evidence that the trial succeeded:
1. Mayo clinic, the location of lenzilumab's study, has had phenomenal Covid results. 1% of their patients passed away vs 3% national average. The Mayo Clinic is a top notch facility but general good medical care isn't enough to explain such success. But a wunderdrug would explain it.
2. Thermo Fisher is adding $600 million in production facilities to meet Covid demand. This article mentions Humanigen as one of two companies that could be for: https://www.fiercepharma.com/manufacturing/thermo-fisher-lays-out-600m-to-more-than-double-capacity-for-biologics-and-vaccines
3. On March 5th, two South Korean companies that HGEN has partnered with both had their stocks rise which caused HGEN's stock to shoot from $15 to $22 in premarket trading. Insider information has many ways to leak. HGEN talking to our partners is one way. Just because investors are in the dark doesn't mean things aren't happening behind the scenes with manufacturing and commercialization.
4. The UK study coming out confirming that targeting GM-CSF is the way to treat Covid. This is history in the making.
Stock purchases from stimulus checks will start Monday:
https://www.bloomberg.com/news/articles/2021-03-13/-stimmy-is-setting-stage-for-next-wave-of-retail-stock-frenzy?srnd=premium
The retail buying may come as soon as Monday, giving the Nasdaq 100 Index new wind after it fell into a correction earlier this month amid a crash for some of the market’s most speculative names. The checks “could offer a short-term ‘shot in the arm’ to a market that was otherwise looking run-down and vulnerable to a sell-off,” said Sam Stovall, the chief investment strategist at CFRA Research.
Individuals age 25 to 34 with online brokerage accounts plan to use about 50% of their stimulus to buy stocks, according to a survey this month by Deutsche Bank.
I feel like this week could be a week where HGEN's stock price goes up a dollar or two each day or even more. The news came out Wednesday that GM-CSF is the key to stopping Severe Covid and death. I'm sure some people dug into the issue this weekend looking for potential investments. Lenzilumab is the premier GM-CSF inhibitor drug. All serious GM-CSF investment research is going to lead to lenzilumab and HGEN.
It is kind of neat seeing something very specific happen in the scientific world and realize that you are watching history in the making. GM-CSF is going to be talked about by everyday folks within a few months the same way everyday folks now talk about cytokine storms.
Leronlimab did not fail a thing
I will no longer believe that we are locked into an algorithm with CYDY that suppresses our share price.
Even though we have still not broken out of the algorithm that pegs our share price to CYDY's share price, we are finally trading at more than 5 times the price of CYDY (which is to say that our share price is higher than theirs' on a pre-reverse split basis). That sub-CYDY price valuation has been a major burn in my backside, ever since we announced the reverse.
Someone is accumulating. Is this the start of the investments that are going to come in when people receive the news that GM-CSF is the key to stopping Covid?
Wonder if a prison snitch might have told some tales from when he was incarcerated.
Total b.s. Just another short tactic before the coming squeeze!
https://www.sec.gov/smallbusiness/goingpublic/officersanddirectors
Beneficial ownership reports
If your company has registered a class of its equity securities under the Exchange Act, shareholders who acquire more than 5% of the outstanding shares of that class must file beneficial owner reports on Schedule 13D or 13G until their holdings drop below 5%. These filings contain background information about the shareholders who file them as well as their investment intentions, providing investors and the company with information about accumulations of securities that may potentially change or influence company management and policies.
Transaction reporting by officers, directors and 10% shareholders
Section 16 of the Exchange Act applies to an SEC reporting company's directors and officers, as well as shareholders who own more than 10% of a class of the company's equity securities registered under the Exchange Act. The rules under Section 16 require these “insiders” to report most of their transactions involving the company's equity securities to the SEC within two business days on Forms 3, 4 or 5.
hgen targets GM-CSF
https://www.bbc.com/news/health-56352128.
You: "Does leronlimab affect GM-CSF?"
Why yes, yes it does. Ohm20 has discussed this before. You probably knew that already. Good Luck!
Yesterday's trial news from Imperial College London shows that the protein GM-CSF is the specific cytokine responsible for Severe Covid and death. Does leronlimab affect GM-CSF? I know that HGEN's lenzilumab is a GM-CSF inhibitor. It seems leronlimab needs to affect GM-CSF if it is going to having a chance at good results. https://www.bbc.com/news/health-56352128